• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.

作者信息

Iqbal Shumaila Muhammad, Stecklein Kathryn, Sarow Joseph, Krabak Michael, Hillengass Jens, McCarthy Philip

机构信息

Department of Internal Medicine, University at Buffalo, Sisters of Charity Hospital, Buffalo, NY.

Department of Oncology Pharmacy, Roswell Park Comprehensive Cancer Centre, Buffalo, NY.

出版信息

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.

DOI:10.1016/j.clml.2018.08.021
PMID:30337238
Abstract
摘要

相似文献

1
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.埃罗妥珠单抗联合来那度胺和地塞米松治疗难治性免疫球蛋白轻链淀粉样变性伴多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.
2
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.NK 细胞激活的机制和 SLAMF7 抗体依鲁替尼在多发性骨髓瘤中的治疗活性。
Front Immunol. 2018 Nov 5;9:2551. doi: 10.3389/fimmu.2018.02551. eCollection 2018.
3
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.依洛尤单抗治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2021 May;17(13):1581-1591. doi: 10.2217/fon-2020-1088. Epub 2021 Jan 22.
4
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.埃罗妥珠单抗联合来那度胺和地塞米松治疗复发多发性骨髓瘤患者：随机、开放标签、1b-2期剂量递增研究的最终2期结果
Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.
5
Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.依鲁替尼单抗：用于复发和/或难治性多发性骨髓瘤的治疗。
Drugs. 2018 Sep;78(14):1481-1488. doi: 10.1007/s40265-018-0969-4.
6
Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.依洛珠单抗最新进展：一种新型抗 SLAMF7 单克隆抗体，用于治疗多发性骨髓瘤。
Expert Opin Biol Ther. 2016 Oct;16(10):1291-301. doi: 10.1080/14712598.2016.1221920. Epub 2016 Aug 17.
7
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.依鲁替尼联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项多中心、开放标签的 II 期研究
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
8
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.帕博利珠单抗联合来那度胺及低剂量地塞米松治疗复发或难治性多发性骨髓瘤：I期KEYNOTE-023研究
Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15.
9
Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.达雷妥尤单抗、来那度胺和地塞米松用于新诊断的与多发性骨髓瘤相关的系统性轻链淀粉样变患者
Br J Haematol. 2022 Aug;198(3):e38-e41. doi: 10.1111/bjh.18234. Epub 2022 May 7.
10
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.帕博利珠单抗、来那度胺和地塞米松用于高危多发性骨髓瘤患者自体移植后治疗
Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.

引用本文的文献

1
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions.心脏淀粉样变性的病因治疗：治疗标准与未来方向
Curr Heart Fail Rep. 2025 Apr 15;22(1):16. doi: 10.1007/s11897-025-00701-4.
2
Cardiac amyloidosis: Innovations in diagnosis and treatment.心脏淀粉样变性：诊断与治疗的创新进展
Eur Heart J Suppl. 2025 Feb 19;27(Suppl 1):i88-i97. doi: 10.1093/eurheartjsupp/suae111. eCollection 2025 Feb.
3
CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy.
自然杀伤细胞中CS1表达模式及浆细胞发育异常中的相关因素：对埃罗妥珠单抗治疗和嵌合抗原受体T细胞疗效的影响。
J Cancer. 2024 Apr 8;15(10):3065-3075. doi: 10.7150/jca.93637. eCollection 2024.
4
Immune Therapies in AL Amyloidosis-A Glimpse to the Future.AL型淀粉样变性的免疫疗法——展望未来
Cancers (Basel). 2024 Apr 22;16(8):1605. doi: 10.3390/cancers16081605.
5
Cardiovascular toxicity from therapies for light chain amyloidosis.轻链淀粉样变性治疗导致的心血管毒性。
Front Cardiovasc Med. 2023 Jul 5;10:1212983. doi: 10.3389/fcvm.2023.1212983. eCollection 2023.
6
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: State-of-the-Art Review.AL型淀粉样变性：当前的化疗和免疫治疗策略：最新综述
JACC CardioOncol. 2021 Oct 19;3(4):467-487. doi: 10.1016/j.jaccao.2021.09.003. eCollection 2021 Oct.
7
AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.心脏病专家和肿瘤学家的AL型淀粉样变性：流行病学、诊断与管理
JACC CardioOncol. 2019 Sep 24;1(1):117-130. doi: 10.1016/j.jaccao.2019.08.002. eCollection 2019 Sep.
8
Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis.心脏淀粉样变的病理生理学和治疗方法。
Circ Res. 2021 May 14;128(10):1554-1575. doi: 10.1161/CIRCRESAHA.121.318187. Epub 2021 May 13.
9
Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management.系统性 AL 淀粉样变性：诊断与管理的当前方法
Hemasphere. 2020 Aug 10;4(4):e454. doi: 10.1097/HS9.0000000000000454. eCollection 2020 Aug.